0
No votes yet
Article

Risk of Metabolic Syndrome, Cardiovascular Disease, and Diabetes in Androgen Deprivation Therapy

Yvonne Leahy
CJON 2008, 12(5), 771-776 DOI: 10.1188/08.CJON.771-776

Men with prostate cancer may be at increased risk for metabolic syndrome, cardiovascular disease, and diabetes from androgen deprivation therapy (ADT). This article reviews current literature related to potential adverse effects of using ADT for localized prostate cancer. The use of gonadotropin-releasing hormone agonist therapy for prostate cancer in the early 1990s compared to the late 1990s is addressed. Oncology nurses play an important role in educating men about strategies for preventing and reducing side effects of cancer treatment. Therefore, having knowledge regarding the impact of hormone therapy on men's health will be important to prostate cancer survivors.

References 

Alberti, K. G., Zimmet, P., & Shaw, J. (2005). The metabolic syndrome: A new worldwide definition. <i>Lancet</i>, 366(9491), 1059-1062.

American Heart Association. (2008). <i>Heart disease and stroke statistics—2008 update.</i> Dallas, TX: Author

Appel, S. J., Jones, E. D., & Kennedy-Malone, L. (2004). Central obesity and the metabolic syndrome: Implications for primary care providers. <i>Journal of the American Academy of Nurse Practitioners</i>, 16(8), 335-342.

Barnard, R. J. (2007). Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. <i>American Journal of Clinical Nutrition</i>, 86(3), s889-s893.

Bigaard, J., Tjonneland, A., Thomsen, B. L., Overvad, K., Heitmann, B. L., & Sorensen, T. I. (2003). Waist circumference, BMI, smoking, and mortality in middle-aged men and women. <i>Obesity Research</i>, 11(7), 895-903.

Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., et al. (2006). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. <i>Journal of Clinical Oncology</i>, 24(24), 3979-3983.

Bratt, O. (2002). Hereditary prostate cancer: Clinical aspects. <i>Journal of Urology</i>, 168(3), 906-913.

Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., et al. (2006). Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women's Intervention Nutrition Study. <i>Journal of the National Cancer Institute</i>, 98(24), 1767-1776.

Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003). National practice patterns and time trends in androgen ablation for localized prostate cancer. <i>Journal of the National Cancer Institute</i>, 95(13), 981-989.

Davies, B. J., Walsh, T. J., Ross, P. L., Knight, S. J., Sadetsky, N., Carroll, P. R., et al. (2008). Effect of BMI on primary treatment of prostate cancer. <i>Urology</i>, 72(2), 406-411.

Eri, L. M., Urdal, P., & Bechensteen, A. G. (1995). Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. <i>Journal of Urology</i>, 154(1), 100-104.

Ford, E. S., Giles, W. H., & Mokdad, A. H. (2004). Increasing prevalence of the metabolic syndrome among U. S. adults. <i>Diabetes Care</i>, 27(10), 2444-2449.

Hsing, A. W., Sakoda, L. C., & Chua, S. (2007). Obesity, metabolic syndrome, and prostate cancer. <i>American Journal of Clinical Nutrition</i>, 86(3), s843-s857.

International Diabetes Federation. (2005). <i>The IDF consensus worldwide definition of the metabolic syndrome.</i> Retrieved January 2, 2008, from <a target="_blank" href='http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf'>http://www.idf.o...

Janssen, I., Katzmarzyk, P. T., & Ross, R. (2005). Body mass index is inversely related to mortality in older people after adjustment for waist circumference. <i>Journal of the American Geriatrics Society</i>, 53(12), 2112-2118.

Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. <i>Journal of Clinical Oncology</i>, 24(27), 4448-4456.

Lakka, H. M., Laaksonen, D. E., Lakka, T. A., Niskanen, L. K., Kumpusalo, E., Tuomilchto, J., et al. (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. <i>JAMA</i>, 288(21), 2709-2716.

National Comprehensive Cancer Network. (2008). <i>NCCN Clinical Practice Guidelines in Oncology™: Prostate cancer</i> [v.1.2008]. Retrieved March 1, 2008, from <a target="_blank" href='http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf'>http:/...

Segal, R. J., Reid, R., Chris, S., Proulx, C., Courneya, K., Sigal, R., et al. (2007). Resistance or aerobic exercise in men receiving radiation therapy for prostate cancer: A randomized trial [Abstract 113]. <i>Proceedings of the Prostate Cancer Symposium</i>, American Society of Clinical Oncology, Orlando, FL. Retrieved May 9, 2008, from http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview... <a target="_blank" href='http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview...

Shahinian, V. B., Kuo, Y. F., Freeman, J. L., Orihuela, E., & Goodwin, J. S. (2005). Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. <i>Cancer</i>, 103(8), 1615-1624.

Sizer, F. S., & Whitney, E. N. (2000). <i>Nutrition: Concepts and controversies</i> (8th ed.). Belmont, CA: Wadsworth/Thompson Learning.

Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., et al. (2001). The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. <i>Journal of Clinical Endocrinology and Metabolism</i>, 86(9), 4261-4267.

Smith, M. R. (2007). Androgen deprivation therapy for prostate cancer: New concepts and concerns. <i>Current Opinion in Endocrinology, Diabetes, and Obesity</i>, 14(3) 247-254.

Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., et al. (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. <i>Journal of Clinical Endocrinology and Metabolism</i>, 87(2), 599-603.

Smith, M. R., Lee, H., & Nathan, D. M. (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. <i>Journal of Clinical Endocrinology and Metabolism</i>, 91(4), 1305-1308.

Surveillance, Epidemiology, and End Results Program. (2007). SEER* Stat Database: Incidence-SEER 17 Registries Limited-Use (1973-2005) [Data file]. Retrieved August 26, 2008, from <a target="_blank" href='http://seer.cancer.gov/data'>http://seer.cancer.gov/data</a>

Turner, A. M. (2007). Cardiovascular risk: Motivating behaviour change to reduce it. <i>Practice Nurse</i>, 34, 35-40.

National Institute of Diabetes and Digestive and Kidney Diseases. (2005). National diabetes statistics fact sheet: General information and national estimates on diabetes in the United States, 2005. Bethesda, MD: U. S. Department of Health and Human Services, National Institutes of Health.

Rice, C. A. (2005). Prevention: The most economical way to manage diabetes. <i>Nursing Economics</i>, 23(6), 327-329.

Ries, L. A. G., Melbert, D., Krapcho, M., Stinchcomb, D. G., Howlader, N., Horner, M. J., et al. (Eds.). (2007). SEER cancer statistics review, 1975-2005. Retrieved August 6, 2008, from <a target="_blank" href='http://seer.cancer.gov/csr/1975_2005'>http://seer.cancer.gov/csr/1975_20...